Are psychedelics effective in treating anxiety associated with a lifethreatening disease? by Wilwohl, Kayla
Philadelphia College of Osteopathic Medicine
DigitalCommons@PCOM
PCOM Physician Assistant Studies Student
Scholarship Student Dissertations, Theses and Papers
2018
Are psychedelics effective in treating anxiety
associated with a lifethreatening disease?
Kayla Wilwohl
Philadelphia College of Osteopathic Medicine
Follow this and additional works at: https://digitalcommons.pcom.edu/pa_systematic_reviews
Part of the Medicine and Health Sciences Commons
This Selective Evidence-Based Medicine Review is brought to you for free and open access by the Student Dissertations, Theses and Papers at
DigitalCommons@PCOM. It has been accepted for inclusion in PCOM Physician Assistant Studies Student Scholarship by an authorized
administrator of DigitalCommons@PCOM. For more information, please contact library@pcom.edu.
Recommended Citation
Wilwohl, Kayla, "Are psychedelics effective in treating anxiety associated with a lifethreatening disease?" (2018). PCOM Physician
Assistant Studies Student Scholarship. 308.
https://digitalcommons.pcom.edu/pa_systematic_reviews/308
  
 
 
 
Are psychedelics effective in treating anxiety associated with a life-
threatening disease? 
 
 
Kayla Wilwohl, PA-S 
 
A SELECTIVE EVIDENCE BASED MEDICINE REVIEW 
In Partial Fulfillment of the Requirements for 
The Degree of Master of Science 
In 
Health Sciences – Physician Assistant 
 
Department of Physician Assistant Studies 
Philadelphia College of Osteopathic Medicine 
Philadelphia, Pennsylvania 
 
December 15, 2017 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
ABSTRACT 
 
OBJECTIVE: The objective of this selective Evidence Based Medicine (EBM) review is to 
determine whether or not “Are psychedelics effective in treating anxiety associated with a life-
threatening disease?” 
 
STUDY DESIGN: Review of two double-blind, randomized, placebo-controlled pilot studies 
and one randomized controlled trial (RCT). 
 
DATA SOURCES: All studies were published in peer-reviewed journals found via the use of 
PubMed Database.  
 
OUTCOMES MEASURED: The outcome measured in this EBM was the effect of psilocybin or 
LSD on the reduction in anxiety. Reduction in anxiety was measured using either the Hamilton 
Anxiety Rating Scale (HAM-A) or the State-Trait Anxiety Inventory (STAI). Participants 
subjectively rated their anxiety pre- and post-drug administration. 
 
RESULTS: The results of each study reached statistical significance, indicating psilocybin or 
LSD to be an effective form of treatment for anxiety in patients with a life-threatening disease. 
The study by Gasser et al. showed a significant reduction in state anxiety from baseline to 2 
months post-LSD administration (p = 0.021). Grob et al. showed a significant decrease in trait 
anxiety at the 1-month (p = 0.001) and 3-month (p = 0.03) follow-ups after psilocybin 
administration. Lastly, Griffiths et al. found that 76% of patients administered high-dose 
psilocybin had a >50% reduction in their anxiety 5 weeks after treatment as compared to 24% of 
those participants in the control group, with a number needed to treat (NNT) of 2.   
 
CONCLUSION: Both pilot studies and the RCT included in this review indicate that LSD or 
psilocybin are an effective treatment for anxiety associated with a life-threatening disease.  
 
KEY WORDS: Psilocybin, Lysergic Acid Diethylamide, Anxiety 
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INTRODUCTION 
Anxiety is among the most prevalent mental health disorders in the United States. It is an 
expected, normal, and transient response to stress; however, anxiety is pathologic when it has no 
identifiable internal or external trigger, exceeds a patient’s capacity to bear discomfort, the 
symptoms are persistent, and it results in avoidance and/or withdrawal behaviors. Anxiety is 
characterized by persistent feelings of apprehension and excessive worry, and can be 
accompanied by somatic symptoms (e.g. palpitations, chest tightness, lightheadedness, 
restlessness). It also has the ability to alter one’s cognitive and affective functioning.  
Anxiety disorders are the most common mental illness in the United States. 
Approximately 40 million people older than the age of 18 are affected.1 Individuals with a life-
threatening disease, such as pancreatic cancer or Parkinson’s disease, are especially vulnerable to 
developing anxiety. It is estimated that 2-14% of terminally ill patients suffer from anxiety 
disorders, with generalized anxiety disorder (GAD) and panic disorder being the most common 
manifestations.2 Roughly 25-48% of patients exclusively with cancer experience both 
psychological and physical anxiety-related symptoms.2 Not only is the prevalence of anxiety 
high, but so too is the cost. In the U.S., anxiety disorders have been estimated to cost between 
$42.3 and $46.6 billion annually.3 The mean total medical cost for a patient diagnosed with an 
anxiety disorder is $6,475.3 An estimated total of $18.4 billion has been spent on prescription 
medications for those individuals diagnosed with anxiety or a mood disorder.4 It is also one of the 
most common reasons for psychiatric consultation among those patients suffering from fatal 
illness.2 No recent estimates have been made on the number of annual visits made for anxiety; 
however, a study published in 2002 noted an increase from 9.5 million visits in 1985 to 12.3 
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million visits in 1997-1998, indicating a rising trend in the number of healthcare visits scheduled 
for anxiety-related conditions.5 
Anxiety is thought to arise from an unknown internal stimulus or is an inappropriate or 
excessive response when compared to an external stimulus. The cause of anxiety is multi-
factorial, involving environmental, social, and biological factors. Several environmental and 
social factors can predispose one to anxiety. For instance, more recent stressful life events, 
especially those characterized by illness and death, increase the risk of anxiety and depression.6 In 
patients with a known medical illness, the condition, its complications, and the treatment of the 
illness are all suspected to be causes of anxiety. Biologically, both the hippocampus and 
activation of the amygdala are also noted to have a role in the development of anxiety. 
Connections between the amygdala and pre-frontal cortex are responsible for the conscious 
experience and regulation of emotion.6 Brain imaging studies have demonstrated that individuals 
with anxiety show amplified responses in these areas of the brain when confronted with an 
emotionally intimidating stimulus. This indicates that individuals with anxiety may have a pre-
existing abnormality in the neural connection between the pre-frontal cortex and amygdala that 
predisposes them to anxiety disorders.6 Many neurotransmitters also generate and modulate 
anxiety symptoms, including norepinephrine, serotonin, dopamine, and GABA.  
Many treatments are available to control episodes of anxiety as well as exacerbations of 
anxiety. Most commonly used at the selective serotonin reuptake inhibitors (SSRIs), such as 
paroxetine (Paxil), fluoxetine (Prozac), sertraline (Zoloft), citalopram (Celexa), and escitalopram 
(Lexapro). These medications block the reuptake of serotonin at pre-synaptic receptors. Second 
line medications that have been used are serotonin-norepinephrine (NE) reuptake inhibitors 
(SNRIs). These medications include duloxetine (Cymbalta) and venlafaxine (Effexor), and are 
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similar to SSRIs, but also block the reuptake of NE and dopamine. Benzodiazepines are 
indicated for short-term use in the management of anxiety. These medications include, 
lorazepam (Ativan), alprazolam (Xanax), and diazepam (Valium). The treatment options 
described above are effective in treating anxiety. However, each class of medication has 
demonstrated various gastrointestinal and cardiac side effects (e.g. hypertension) in different 
types of people. Cancer patients, specifically, fail to achieve satisfactory relief from the available 
medications previously listed. Without appropriate treatment, anxiety persists as a serious 
problem for these people. This population thus warrants the need for more effective 
interventions. Psilocybin and LSD are potential alternatives that may be effective in the 
treatment of anxiety associated with cancer.  This paper evaluates two double-blind, randomized, 
placebo-controlled pilot studies and 1 randomized control trial (RCT) surveying the effects of 
psychedelics, specifically psilocybin or lysergic acid diethylamide (LSD), in the treatment of 
anxiety related to a life-threatening disease.  
OBJECTIVE 
The objective of this selective Evidence Based Medicine (EBM) review is to determine 
whether or not “Are psychedelics effective in treating anxiety associated with a life-threatening 
disease?” 
METHODS 
 This investigation looks at two double-blind, randomized, placebo-controlled pilot 
studies and one randomized controlled trial (RCT). The population of the studies used for this 
review includes both men and women diagnosed with a life-threatening disease as well as a 
DSM-IV anxiety disorder diagnosis. Participants across all studies were older than 35 years of 
age. All studies used a psychedelic, either LSD or psilocybin, as the intervention and an active 
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placebo. Active placebos were chosen in order to produce mild and detectable effects of the 
drugs, but were not substantial enough to produce any therapeutic effects. The purpose of the 
active placebo is to aid in the blinding of the study. In Gasser et al., the intervention addressed 
was LSD. LSD was administered orally as capsules consisting of 200 μg. The subjects acted as 
their own control. The comparison group consisted of an active placebo of 20 μg of LSD. In 
Grob et al., the intervention addressed was psilocybin. Subjects were administered active 
psilocybin (0.2 mg/kg). The placebo was niacin (250 mg).8 Griffiths et al. utilized psilocybin as 
the therapeutic intervention. High dose psilocybin (22 or 30 mg/70 kg) was administered orally 
in opaque, size 0 gelatin capsules with lactose as the capsule filler. A placebo-like low dose of 
psilocybin (1 or 3 mg/70 kg) was utilized as the comparison group.9 The main outcome measured 
was a reduction in anxiety as demonstrated by either the State-Trait Anxiety Inventory (STAI) or 
the Hamilton Anxiety Rating Scale (HAM-A).  
The author, using the key words “lysergic diethylamide acid,” “psilocybin,” and 
“anxiety,” carried out a detailed search using the Cochrane Systematic Review and PubMed. All 
studies were published in English in peer-reviewed journals. All studies were published after the 
year of 2010 and were selected based on their relevance to the topic and whether or not they 
included patient oriented evidence that matters (POEMs). Inclusion criteria for this systematic 
review randomized controlled trials. Exclusion criteria included previous Cochrane reviews as 
well as systematic reviews submitted by previous students. Inclusion and exclusion for the 
individual studies are included in Table 1. The statistics of this study used to evaluate patient 
outcomes included t-value, p-value, F-score, RBI, ABI, NNT. All studies used similar statistics 
to evaluate the outcomes where p-value is considered statistically significant if it is < 0.05 or < 
0.025 (two-tailed). The demographics of the studies are included and outlined in Table 1.  
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Table 1: Demographics & Characteristics of Included Studies 
Study Type 
Number 
of 
Patients 
Age 
(years) Inclusion Criteria Exclusion criteria W/D Interventions 
Gasser, et 
al. (2014)7 
double-blind, 
randomized, 
placebo-
controlled 
pilot study 
12 39-64 
y/o 
patients w/ a life-
threatening disease 
with a score greater 
than 40 on either the 
state or trait scale 
on the Spielberger 
State-Trait Anxiety 
Inventory 
current alcohol or drug 
dependence; bipolar I, 
dissociative disorders; 
neurocognitive impairment; 
women pregnant or nursing 
2 lysergic 
diethylamide 
acid (200 μg) 
in capsules 
Grob, et 
al. (2011)8 
double-blind, 
randomized, 
placebo-
controlled 
pilot study 
12 36-58 
y/o 
advanced-stage 
cancer and a DSM-
IV diagnosis of 
acute stress 
disorder, 
generalized anxiety 
disorder, anxiety 
disorder due to 
cancer, or 
adjustment disorder 
with anxiety 
CNS involvement of the 
cancer, severe 
cardiovascular illness, 
untreated HTN, abnormal 
hepatic or renal function, 
DM, life-time history of 
schizophrenia, bipolar 
disease, anxiety or affective 
disorders within 1 year 
prior to the onset of the 
cancer, active cancer 
chemotherapy, antiseizure 
medications, 
insulin/hypoglycemic 
medications, or 
psychotropic medications 2 
weeks prior to treatment 
4 psilocybin (0.2 
mg/kg) with 
100 mL of H2O 
in clear 00 
capsules with 
corn starch 
Griffiths, 
et al. 
(2016)9 
randomized 
controlled 
trial 
56 mean 
age of 
56 y/o 
life-threatening 
cancer diagnosis 
and a DSM-IV 
diagnosis that 
included chronic 
adjustment disorder 
with anxiety, 
chronic adjustment 
disorder with mixed 
anxiety and 
depressed mood, 
dysthymic disorder, 
generalized anxiety 
disorder, or major 
depressive disorder 
CNS involvement of 
cancer, hepatic dysfunction, 
paraneoplastic syndrome, 
uncontrolled HTN, angina, 
EKG abnormality, stroke, 
epilepsy, renal 
insufficiency, DM1, 
pregnant females 
10 psilocybin (22 
or 30 mg/70 
kg) 
administered in 
opaque, size 0 
gelatin capsules 
with lactose as 
the capsule 
filler 
 
OUTCOMES MEASURED 
The main outcome measured in the selected studies is the effectiveness of psychedelics, 
specifically LSD and psilocybin, in the reduction of anxiety associated with a life-threatening 
disease. Gasser et al. and Grob et al. utilized the State-Trait Anxiety Inventory (STAI).7,8 
Participants subjectively rated their anxiety pre- and post-drug administration. The STAI 
measures anxiety by assessing feelings of apprehension, tension, nervousness, and worry.8 The 
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STAI measures state and trait anxiety separately. State anxiety refers to a temporary state of 
anxiety. The state anxiety subscale of the STAI gears its questions towards the patient’s present 
feelings of anxiety. Trait anxiety refers to long-standing and enduring feelings of anxiety. The 
trait anxiety subscale assesses the patient’s overall view of him or herself as a person. The STAI 
has 20 items for assessing trait anxiety and 20 items for state anxiety. All items are rated on a 4-
point scale (e.g., from “Almost Never” to “Almost Always”). Higher scores indicate greater 
anxiety. 
Griffiths et al. utilized the Hamilton Anxiety Rating Scale (HAM-A). HAM-A is a 
clinician-rated scale that consists of 14 items (anxious mood, tension, fears, insomnia, 
intellectual depressed mood, somatic (muscular) symptoms, somatic (sensory) symptoms, 
cardiovascular symptoms, respiratory symptoms, gastrointestinal symptoms, genitourinary 
symptoms, autonomic symptoms, and behavior during the interview). Each item is graded on a 
scale from 0 to 4. The HAM-A score can range from 0 to 56. A score < 17 is indicative of mild 
anxiety, 18-24 indicates mild to moderate anxiety, and 25-30 indicates moderate to severe 
anxiety. 
RESULTS 
Gasser et al. conducted a pilot study that was 12 months in duration. Subjects were 
randomly assigned to an experimental or comparison group. Those in the experimental group (n 
= 8) received 200 μg of LSD. Those in the comparison group were administered 20 μg (n = 4) of 
LSD. This dose of LSD was chosen to produce mild and detectable effects of LSD, but were not 
substantial enough to produce any therapeutic effects. The purpose of using LSD as an active 
placebo was to produce noticeable effects to convince the subject that he/she was receiving the 
legitimate treatment. All subjects were blinded to the condition assignment. LSD was 
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administered to the subjects at two separate times, 2-3 weeks apart, in the setting of a quiet and 
safe private practice office. The STAI was administered to the subjects prior to treatment, after 
each experimental session, and then again at a 2-month follow-up. After the 2-month follow-up, 
the conditions were revealed to the subjects. Those subjects that received the placebo were 
offered the opportunity to crossover to receive the active intervention; however, this was not 
blinded. All subjects, including those that participated in the open-label crossover, were required 
to complete a 12-month follow-up of the STAI. At the conclusion of the 2-month follow-up, all 
subjects that entered the trial were accounted for; however, at the 12-month follow-up after the 
open-label crossover, only 6 of the 8 subjects in the original experimental group completed the 
12-month follow-up evaluation (1 subject died due to cancer, 1 subject did not complete the 
evaluation). One subject from the active placebo group was not analyzed due to the development 
of exclusion criteria. Therefore, only 3 subjects from the active placebo completed the open-label 
crossover. Those 3 subjects participated in the 12-month follow-up evaluation. Thus, only 9 total 
subjects completed the 12-month follow-up. 
The effect of LSD on anxiety was measured utilizing the STAI. Analysis of variance 
(ANOVA) was used to assess for significant changes in anxiety from baseline to post-LSD 
administration. State and trait anxiety were analyzed separately. Significance was demonstrated 
by p < 0.025 (two-tailed). Prior to treatment, no significant difference was found in the mean 
STAI-Trait scores (p = 0.261) or STAI-State scores (p = 0.563) between the groups at baseline. 
There was no significant difference in trait anxiety from baseline to 2 months post-LSD 
administration in the experimental group (F(2,18) = 4.151, p = 0.033). Those subjects receiving 
the active placebo experienced increased trait anxiety, but this was not found to be statistically 
significant. There was a significant difference in state anxiety from baseline to 2 months post-
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LSD administration in the experimental group (F(2,18) = 4.846, p = 0.021), see Table 2. The F-
score is higher than its respective F-critical value, indicating that LSD was effective in reducing 
state anxiety 2 months after drug administration. The p-value indicates that this effect is 
significant (p < 0.025). Those individuals receiving the active placebo experienced an elevation 
in state anxiety, but again, this was not found to be statistically significant. At the 12-month 
follow-up after the open-label crossover, the mean difference between state anxiety at 2 months 
and state anxiety at 12 months was 1.0 (p = 0.531). This indicates there was no significant 
change in state anxiety from 2 months to 12 months, indicating that the effect of LSD in reducing 
state anxiety was maintained over time. 
Table 2. Mean Change in STAI-State or STAI-Trait Anxiety as Measured by Gasser et al. 2014 
 Baseline 2-Month Follow-Up 12-Month Follow-Up Experimental Placebo Experimental Placebo All 
STAI-Trait 53.2 43.3 45.2 49.0 41.1 
STAI-State 53.1 47.7 41.5* 51.7 36.1 
*p = 0.021 
Grob et al. conducted a pilot study that was 6 months in duration. Subjects participated in 
two experimental sessions that took place several weeks apart. Subjects acted as his/her own 
control, and were informed that they would receive 0.2 mg/kg of psilocybin during one session 
and 200 mg of niacin during the other session; however, the order in which the subjects received 
those treatments was randomized. The STAI was administered to and completed by participants 
1 day prior to treatment, 6 hours after treatment, 1 day after treatment, and 2 weeks after 
treatment. The STAI was then also administered at monthly intervals for 6 months following the 
study. A t-test was used to compare the STAI at baseline to the STAI values 1, 2, 3, 4, 5, and 6 
months following psilocybin treatment. The t-test determines if the 2 groups being compared 
(pre-psilocybin administration and post-psilocybin administration) differ significantly. The t-
value is compared to a critical value. If the intervention in question has an effect, the t-value will 
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be greater than the critical value. The significance of this effect is then determined by a p-value. 
In this study, p < 0.05 was considered clinically significant.  At the conclusion of the 3-month 
follow-up, all subjects that entered the trial were accounted for; however, only 8 of the 12 
subjects completed the 6-month follow-up STAI (2 participants died and 2 were too sick to 
continue participating). 
The numerical values of the STAI mean scores, as well as the mean change from 
baseline, were not presented within the article. Data were presented graphically. The STAI did 
not show any significant changes in state or trait anxiety from baseline to 2 weeks after 
psilocybin administration. There was a decrease in state anxiety 6 h following psilocybin 
administration, but it was not found to be clinically significant. There were no significant 
findings of the effect of psilocybin on state anxiety for follow-up. However, there was a decrease 
in trait anxiety at the 1-month follow-up (t11 = 4.36, p = 0.001) and 3-month follow-up (t10 = 2.55, 
p = 0.03). The t-scores indicate that the psilocybin had an effect on STAI trait anxiety 1 and 3 
months following treatment. The t-scores from the 1- and 3-month follow-ups are higher than 
their respective critical t-values. Therefore, the large t-scores demonstrate that psilocybin had a 
large effect in reducing trait anxiety 1 and 3 months following psilocybin administration. 
Psilocybin’s effect was large, and the p-values indicate that its effect in reducing trait anxiety is 
significant (p < 0.05). 
Griffiths et al. conducted a RCT that was 6 months in duration.9 The subjects acted as 
their own controls. Subjects were told they would be receiving psilocybin, but the order of 
administration of the treatments was randomized. In this study, a low dose and high dose of 
psilocybin was used. Subjects in the comparison group were administered a placebo-like low 
dose of psilocybin (1 or 3 mg/70 kg). The low dose was decreased from 3 to 1 mg/70 kg after 
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concern that the 3 mg/70 kg dose may show significant therapeutic effects, and thus would not 
be an inactive placebo. Subjects in the experimental group were administered 22 or 30 mg/70 kg. 
The high dose was decreased from 30 to 22 mg/70 kg after 2 of the first 3 participants that 
received the 30 mg/70 kg dose of psilocybin were removed from the study (1 subject vomited 
shortly after capsule administration and 1 left due to personal reasons). The study also indicated 
that psychologically challenging experiences were more likely to occur with a 30 mg/70 kg dose 
of psilocybin. 
A clinical response to the psilocybin was defined as a >50% decrease in the HAM-A 
score relative to baseline. Five weeks after the first session and prior to crossover, there was a 
significant difference between subjects in the High-Dose-1st group compared to subjects in the 
Low-Dose-1st group. Significance was indicated by p < 0.001. Approximately 76% of patients 
administered the high-dose psilocybin (22 or 30 mg/70 kg) had a >50% reduction in their anxiety 
5 weeks after treatment as compared to 24% of those participants receiving the low-dose 
psilocybin. The NNT was calculated to be 2 (see Table 3). This positive number indicates that 
two patients are needed to treat in order for one patient to have a ≥50% decrease in their anxiety 
(as measured with the HAM-A score) compared to the placebo. 
Table 3: Efficacy of Psilocybin in the Treatment of Anxiety Associated with a Life-Threatening 
Disease as Measured by Griffiths et al. 2016 
Study 
Control 
Event Rate 
(CER) 
Experiment 
Event Rate 
(EER) 
Relative Benefit 
Increase (RBI) 
Absolute Benefit 
Increase (ABI) 
Number 
Needed to 
Treat (NNT) 
p-value 
Griffiths et 
al. (2016) 0.24 0.76 2.2 0.52 2 < 0.001 
 
DISCUSSION 
The three RCTs analyzed in this systematic review demonstrated a significant reduction 
in state or trait anxiety through the administration of either LSD or psilocybin.7,8,9 Lysergic acid 
diethylamide is a semisynthetic compound that produces many psychosensory changes, such as 
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increased sensory perception and hallucinations, when administered in large doses. It exhibits its 
psychedelic effects through the activation of 5-HT2A receptors.7 Psilocybin is a natural 
hallucinogen found in various types of mushrooms. It is a 5-HT2A receptor agonist that, when 
administered in larger doses, produces fluctuations in thoughts, perceptions, and emotions.8,9 
There are no current uses for psilocybin and LSD in medicine today. They are considered “street 
drugs” used primarily for the purpose of experiencing euphoria. Both drugs are frequently 
associated with triggering panic attacks or feelings of extreme anxiety when used in excess. 
However, in a controlled environment, when LSD and psilocybin are administered at higher 
doses, it is thought that they induce moments of catharsis.7 These drugs are capable of provoking 
powerful spiritual experiences, during which users feel they have come in contact with a greater 
existence and sense of liberation.7,8,9 It is these psychosensory effects of LSD and psilocybin that 
enable those with anxiety to persevere through the mental and emotional burden that they carry. 
Therefore, by establishing an appropriate treatment protocol and therapeutic window of both 
LSD and psilocybin, these drugs can serve as effective anxiolytics, especially in those patients 
with a terminal disease.  
Both LSD and psilocybin are not currently approved for use in medicine by the FDA. 
Furthermore, they are on the illicit market and are illegal in the U.S. due to their high potential 
for abuse and side effect profile. However, psychedelic properties of these drugs in a controlled 
setting may play a role in the reduction of anxiety. Serotonin deficiency is a proposed causal 
theory of anxiety.6 LSD and psilocybin exhibit their psychedelic effects through the activation of 
5-HT2A receptors.7,8,9 In activating 5-HT2A receptors, these drugs may also stimulate the release of 
more serotonin, thus replenishing the serotonin that is lacking in those individuals with anxiety.  
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It is important to acknowledge the limitations that exist across each of the studies. 
Although the participants were kept blind, when administering a hallucinogenic drug like 
psilocybin or LSD, the blinding of each of the studies was challenged. Psilocybin and LSD, 
when compared to the alternative placebo, produced discriminable effects; therefore, the order in 
which the drugs were administered was made apparent to some of the subjects. Across all 
studies, a strict exclusion criteria were also used, resulting in a small sample size. A small 
sample size reduces the precision of statistics and does not adequately reflect an entire 
population. The population addressed is also a challenging population due to their advanced-
stage cancer diagnoses. When advanced, cancer has the potential to alter the patients’ physical 
and mental states, thus potentially altering the patients’ overall interpretations of the therapy.  
CONCLUSION 
Psilocybin and LSD are effective alternatives for the treatment of anxiety associated with 
a life-threatening disease. The randomized controlled trials analyzed in this systematic review 
showed significant reduction in anxiety after the administration of psilocybin or LSD. Although 
not specifically addressed in this systematic review, psychotherapy in addition to the use of 
psychedelics yields the most effective treatment for anxiety.7,8,9  
Despite the promising results presented within each of these articles, further research is 
warranted to draw conclusions regarding the best treatment protocol. Given the hallucinogenic 
properties of these drugs, it is important to establish a therapeutic window that proves most 
beneficial without eliciting undesired psychical and psychological side effects, such as tremors, 
hyperglycemia, hyperreflexia, visual hallucinations, suicidal ideations, etc. The populations 
enrolled in each of the studies were substantially limited due to a strict inclusion/exclusion 
criteria. Future studies should aim to broaden the inclusion/exclusion criteria to include a wider 
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and more generalized population of individuals affected by anxiety. By enrolling a wider range 
of subjects, psychedelics will not only be used for anxiety associated with a terminal disease, but 
are also likely to be utilized for the treatment of anxiety in the generalized population. 
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